Med BioGene and Duke to Jointly Develop Biomarkers for Lymphoma, Leukemia | GenomeWeb
NEW YORK (GenomeWeb News) – Med BioGene this week said it has entered into a research collaboration and option agreement with Duke University to further develop and validate genetic biomarkers for lymphoma and leukemia.
 
Under the terms of the collaboration, which will use MBI’s gene expression-profiling system, Duke will provide MBI a certain number of samples from patients with clinically confirmed lymphoma and leukemia for genetic analysis.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.